Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis — Fair Value, Risk & Moat Rating
NMS · Healthcare · Biotechnology
Is Regeneron Pharmaceuticals, Inc. a safe investment right now?
Regeneron Pharmaceuticals, Inc.'s Altman Z-Score of 7.51 places it in the safe zone. Our fair value estimate is $655.61 (Fairly Valued). Moat rating: 3.4/5 stars.
Could Regeneron Pharmaceuticals, Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 7.51 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives REGN's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.3366 | 1.2 | 0.4 |
| B · Retained Earnings / Total Assets | RE / TA | 0.8826 | 1.4 | 1.24 |
| C · EBIT / Total Assets | EBIT / TA | 0.13 | 3.3 | 0.43 |
| D · Market Cap / Total Liabilities | MCap / TL | 8.4853 | 0.6 | 5.09 |
| E · Revenue / Total Assets | Rev / TA | 0.3536 | 1.0 | 0.35 |
How has REGN's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 9.84 | Safe |
| 2023 | 9.22 | Safe |
| 2024 | 8.07 | Safe |
| 2025 | 7.51 | Safe |
Source: Calculated from REGN's latest 10-K filing on SEC EDGAR.
What is Regeneron Pharmaceuticals, Inc. actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $42.85 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $41.48 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $44.91 | 28 analysts consensus |
| Trailing P/E | 18.0x | Current market pricing |
| Fair P/E (β discount) | 15.3x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Growing | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $875.45 (28 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Regeneron Pharmaceuticals, Inc. have a durable competitive advantage?
Moat rating: 3.4/5.
What makes up REGN's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 4/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is REGN's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 20.0% | — |
| 2023 | 15.3% | Declining |
| 2024 | 15.4% | Stable |
| 2025 | 15.9% | Stable |
Source: ROIC calculated from SEC EDGAR filings.
Is Regeneron Pharmaceuticals, Inc.'s dividend safe?
Can Regeneron Pharmaceuticals, Inc. afford its dividend?
Payout ratio is 8.5%. FCF covers the dividend 0.0x. 2 consecutive years of payments.
Regeneron Pharmaceuticals, Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $12.2B | Rising |
| Net Income | $4.5B | $4.4B | $4.3B | Stable |
| Free Cash Flow | $3.8B | $3.5B | $3.4B | Rising |
| Gross Margin | 85.4% | 86.1% | 87.2% | Stable |
Recent events that affect our REGN analysis
REGN earnings report scheduled
Upcoming report. Consensus EPS estimate: $8.87. Revenue estimate: $3.48B. Our current Fair Value: $655.61 — a significant beat or miss could shift this estimate.
REGN analyst consensus: 76% bullish (22 of 29 analysts)
4 Strong Buy, 18 Buy, 7 Hold, 0 Sell, 0 Strong Sell. Consensus target: $875.45 (17.3% upside). Compare with our independent Fair Value: $655.61.
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN paid $0.9400/share dividend
Dividend Safety Grade: C. Payout ratio: 8.5%.
REGN filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
REGN beat EPS estimates by 6.4%
Reported EPS: $11.44 vs estimate $10.75. Earnings strength supports our Fair Value of $655.61 (12.2% below current price).
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN paid $0.8800/share dividend
Dividend Safety Grade: C. Payout ratio: 8.5%.
REGN beat EPS estimates by 22.7%
Reported EPS: $11.83 vs estimate $9.64. Earnings strength supports our Fair Value of $655.61 (12.2% below current price).
REGN filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN paid $0.8800/share dividend
Dividend Safety Grade: C. Payout ratio: 8.5%.
REGN beat EPS estimates by 52.7%
Reported EPS: $12.89 vs estimate $8.44. Earnings strength supports our Fair Value of $655.61 (12.2% below current price).
REGN filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN paid $0.8800/share dividend
Dividend Safety Grade: C. Payout ratio: 8.5%.
REGN missed EPS estimates by 3.0%
Reported EPS: $8.22 vs estimate $8.48. Our Fair Value of $655.61 may face downward pressure if the trend continues.
REGN filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN paid $0.8800/share dividend
Dividend Safety Grade: C. Payout ratio: 8.5%.
REGN filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
REGN beat EPS estimates by 7.8%
Reported EPS: $12.07 vs estimate $11.19. Earnings strength supports our Fair Value of $655.61 (12.2% below current price).
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
REGN filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Regeneron Pharmaceuticals, Inc.
What is Regeneron Pharmaceuticals, Inc. stock price today?
Regeneron Pharmaceuticals, Inc. (REGN) stock price is $746.58 as of the latest market close, traded on the NASDAQ exchange.
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. It develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
What is Regeneron Pharmaceuticals, Inc. market cap?
Regeneron Pharmaceuticals, Inc. has a market capitalization of $78.93B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is REGN in?
Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. It trades on the NASDAQ under the ticker symbol REGN.
Is REGN stock overvalued or undervalued?
Based on our valuation model, Regeneron Pharmaceuticals, Inc. trades 13.9% above our fair value estimate — potentially overvalued.
- FairValueLabs Fair Value: $655.61
- Current Price: $746.58
- Valuation Zone: Fairly Valued
What is REGN stock forecast and analyst target price?
Based on 28 Wall Street analysts, the consensus price target for Regeneron Pharmaceuticals, Inc. is $875.45, implying upside of 17.3% from the current price.
- Analyst High Target: $1057.00
- Analyst Low Target: $730.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Regeneron Pharmaceuticals, Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Regeneron Pharmaceuticals, Inc.:
- Revenue growth (current year est.): 9.7%
- EPS growth (current year est.): 1.4%
- Revenue growth (next year est.): 10.3%
- EPS growth (next year est.): 22.1%
What are Regeneron Pharmaceuticals, Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $14.3B | Rising |
| Net Income | $4.5B | Stable |
| Free Cash Flow | $3.8B | Rising |
| Gross Margin | 85.4% | Stable |
What is REGN's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 18.0x
- Forward P/E (next 12 months est.): 14.2x
- FairValueLabs Fair P/E: 15.3x
How volatile is REGN stock?
Regeneron Pharmaceuticals, Inc. has a beta of 0.40, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Regeneron Pharmaceuticals, Inc. have?
Regeneron Pharmaceuticals, Inc.'s balance sheet shows:
- Total Cash: $8.61B
- Total Debt: $2.97B
- Net Cash Position: $5.63B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Regeneron Pharmaceuticals, Inc.'s free cash flow?
Regeneron Pharmaceuticals, Inc. generated $3.26B in trailing twelve-month free cash flow (from $4.98B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Regeneron Pharmaceuticals, Inc. pay a dividend, and is it safe?
Yes, Regeneron Pharmaceuticals, Inc. pays a regular dividend. Here are the key metrics:
- Dividend Yield: 0.5%
- Payout Ratio: 8.5%
- Consecutive Years Paid: 2
- 5-Year Dividend Growth: 0.0%
- FairValueLabs Safety Grade: C
Is Regeneron Pharmaceuticals, Inc. at risk of going bankrupt?
Regeneron Pharmaceuticals, Inc.'s Altman Z-Score is 7.51, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Regeneron Pharmaceuticals, Inc. have a durable competitive advantage?
Regeneron Pharmaceuticals, Inc. scores 3.4/5 stars (Narrow moat) in our moat analysis:
- ROIC Stability: 4/5
- Gross Margin Trend: 3/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is REGN's return on equity (ROE)?
Regeneron Pharmaceuticals, Inc.'s return on equity is 14.9%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy REGN stock?
REGN shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol REGN
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is REGN a value stock or speculative?
FairValueLabs classifies Regeneron Pharmaceuticals, Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Regeneron Pharmaceuticals, Inc.?
The current CEO of Regeneron Pharmaceuticals, Inc. is Dr. Leonard S. Schleifer M.D., Ph.D..
What is REGN's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $41.51
- Forward EPS (next 12 months est.): $52.54
- Analyst consensus EPS (this year): $44.91
- Analyst consensus EPS (next year): $47.55
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
REGN analysis methodology: How we calculate fair value, Z-Scores, and moat ratings